Drug Trial Radar · NCT03815058
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Dec 21, 2018
Primary completion
Jan 21, 2025
Study completion Jan 21, 2025
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Jan 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
Conditions
- Advanced Melanoma
Interventions
Autogene cevumeranBiological
Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
PembrolizumabDrug
Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After RandomizationTime frame: From randomization to PD or death (up to approximately 60 months)
Locations
41 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
University of California San Diego Moores Cancer Center
La Jolla, California
UCSF Comprehensive Cancer Ctr
San Francisco, California
University of Colorado
Denver, Colorado
Cancer Specialists
Jacksonville, Florida
Moffitt McKinley Outpatient Center
Tampa, Florida
Atlanta Cancer Care
Alpharetta, Georgia
Northwestern University
Chicago, Illinois
Massachusetts General Hospital.
Boston, Massachusetts
Washington University
St Louis, Missouri
Case Western Research University
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Intermountain Surgical Oncology
Murray, Utah
Huntsman Cancer Institute
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
Liverpool Hospital
Liverpool, New South Wales, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
St. John of God - Subiaco Hospital
Subiaco, Western Australia, Australia
Antwerp University Hospital
Edegem, Belgium
ZAS Sint Augustinus Wilrijk
Wilrijk, Belgium
Elbe Kliniken Stade-Buxtehude GmbH
Buxtehude, Germany
Universitätsklinikum Koeln
Cologne, Germany
Universitatsklinikum Eppendorf
Hamburg, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Uni Schleswig-Holstein
Lübeck, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Hautklinik und Poliklinik
Mainz, Germany
Med. Fakultat Mannheim der Universitat Heidelberg
Mannheim, Germany
Fachklinik Hornheide
Münster, Germany
Universitätshautk. Tübingen
Tübingen, Germany
Instituto Oncológico Dr. Rosell
Barcelona, Spain
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.